DOCSLIB.ORG

Annual Information Form

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Information Form Annual Information Form Fiscal Year Ended April 30, 2017 July 20, 2017 Table of Contents Note Regarding Forward-Looking Information ......................................................................................................................... 4 Corporate Structure ................................................................................................................................................................... 6 Name and Incorporation ............................................................................................................................................................................ 6 Inter-Corporate Relationships .................................................................................................................................................................... 6 Description of Business ............................................................................................................................................................. 6 The Drug Development Process ................................................................................................................................................................ 6 Resverlogix Current Development Stage: Phase 3 Enrolling ................................................................................................................... 7 Apabetalone (RVX-208) .............................................................................................................................................................................. 8 Epigenetic Mechanism of Action: Single Therapeutic Target with Multiple Biological Effects ............................................................... 8 BET Inhibition Targets Pathways and Markers That Are Linked to CVD .................................................................................................. 9 Resverlogix’s Drug Development Strategy and Commercial Rationale ................................................................................................ 11 Cardiovascular Disease .......................................................................................................................................................................... 12 Chronic Kidney Disease and End-Stage Renal Disease ........................................................................................................................ 13 Diabetes Mellitus .................................................................................................................................................................................... 13 Fabry Disease .......................................................................................................................................................................................... 13 Neurodegenerative Disease ................................................................................................................................................................... 14 Competitive Environment........................................................................................................................................................................ 14 Key Products in Development (Resverlogix and Competitors) .............................................................................................................. 16 General Development of the Business ................................................................................................................................... 16 Recent Clinical Developments ................................................................................................................................................................ 16 Summary of Phase 2 Clinical Trials ........................................................................................................................................................ 21 Completed Apabetalone (RVX-208) Clinical Trials ................................................................................................................................. 22 Current or Planned Apabetalone (RVX-208) Clinical Trials ................................................................................................................... 23 Scientific Developments ......................................................................................................................................................................... 23 Potential Orphan Disease Indications .................................................................................................................................................... 24 Regulatory Affairs .................................................................................................................................................................................... 25 Intellectual Property ................................................................................................................................................................................ 25 Clinical and Scientific Advisory Boards .................................................................................................................................................. 25 Financing ................................................................................................................................................................................................. 28 Licensing .................................................................................................................................................................................................. 29 Risk Factors ............................................................................................................................................................................. 30 Risks Relating to Our Business............................................................................................................................................................... 30 Risks Relating to our Intellectual Property ............................................................................................................................................. 39 Risks Relating to Owning our Common Shares ..................................................................................................................................... 40 Dividends.................................................................................................................................................................................. 41 Description of Capital Structure .............................................................................................................................................. 41 Common Shares ...................................................................................................................................................................................... 41 Preferred Shares ..................................................................................................................................................................................... 41 Market for Securities ............................................................................................................................................................... 43 Escrowed Securities and Securities Subject to Contractual Restrictions on Transfer ........................................................ 43 2 Directors and Executive Officers ............................................................................................................................................. 44 Name, Occupation and Security Holdings .............................................................................................................................................. 44 Audit Committee Matters ........................................................................................................................................................................ 45 Cease Trade Orders, Bankruptcies, Penalties or Sanctions ................................................................................................................. 46 Conflicts of Interest ................................................................................................................................................................................. 47 Interests of Management and Others in Material Transactions ........................................................................................... 47 Transfer Agent and Registrar .................................................................................................................................................. 47 Material Contracts ................................................................................................................................................................... 48 Interests of Experts .................................................................................................................................................................. 48 Additional Information ............................................................................................................................................................. 48 Schedule “A” – Audit and Finance Committee Charter ......................................................................................................... 49 Glossary ...................................................................................................................................................................................
Load more

Recommended publications
  • Evidence for Lysine Acetylation in the Coat Protein of a Polerovirus
    Journal of General Virology (2014), 95, 2321–2327 DOI 10.1099/vir.0.066514-0 Short Evidence for lysine acetylation in the coat protein of Communication a polerovirus Michelle Cilia,1,2,3 Richard Johnson,4 Michelle Sweeney,3 Stacy L. DeBlasio,1,3 James E. Bruce,4 Michael J. MacCoss4 and Stewart M. Gray1,2 Correspondence 1USDA-Agricultural Research Service, Ithaca, NY 14853, USA Michelle Cilia 2Department of Plant Pathology and Plant-Microbe Biology, Cornell University, Ithaca, [email protected] NY 14853, USA 3Boyce Thompson Institute for Plant Research, Ithaca, NY 14853, USA 4Department of Genome Sciences, University of Washington, Seattle, WA 98109, USA Virions of the RPV strain of Cereal yellow dwarf virus-RPV were purified from infected oat tissue and analysed by MS. Two conserved residues, K147 and K181, in the virus coat protein, were confidently identified to contain epsilon-N-acetyl groups. While no functional data are available for K147, K181 lies within an interfacial region critical for virion assembly and stability. The signature immonium ion at m/z 126.0919 demonstrated the presence of N-acetyllysine, and the sequence fragment ions enabled an unambiguous assignment of the epsilon-N-acetyl modification on K181. Received 4 April 2014 We hypothesize that selection favours acetylation of K181 in a fraction of coat protein monomers Accepted 13 June 2014 to stabilize the capsid by promoting intermonomer salt bridge formation. Potato leafroll virus (PLRV) and the barley/cereal/maize encapsidation of one species’ RNA in the virion of another yellow dwarf viruses, members of the Luteoviridae and species. Such manipulation can result in an expansion of referred to hereafter as luteovirids, are globally important potential aphid species that can transmit the virus.
    [Show full text]
  • N-Acetylation of Arginine-Rich Hepatoma Histones1
    [CANCER RESEARCH 31, 468-470, April 1971] N-Acetylation of Arginine-rich Hepatoma Histones1 Paul Byvoetand Harold P. Morris Cellular and Molecular Biology, Division of Biological Sciences, University of Florida, Gainesville, Florida ¡P.B.¡,and Department of Biochemistry, Howard University College of Medicine. Washington, D. C. 20001 ¡H.P.M./ SUMMARY represents a fraction of the total number of sites available for acetylation (2). Previous work in this laboratory has shown that decay rates On the other hand, Starbuck et al. (11) have purified of histones and DNA isolated from deoxyribonucleoprotein of histone fractions which were either 100% acetylated at the normal and neoplastic rat tissues were approximately equal, NH2-terminal end or not at all. In addition, when isolated indicating that not only DNA but the nucleohistone complex nuclei were incubated in the presence of radioactive acetate, as a whole is metabolically inert. In contrast, the vV-acetyl incorporation of label appeared to occur primarily in groups in the combined arginine and slightly lysine-rich e-jV-acetyllysine of histones (6, 12). Thus far, all evidence histones from these same tissues were found to turn over at would therefore lead to the conclusion that the e-jV-acetyl much faster rates than whole histones or DNA, with exception groups on the internal lysine residues are metabolically active, of the Novikoff hepatoma, in which this turnover was wheras the a-jV-acetyl groups at the NH2-terminal ends are remarkably slow, approaching that of the histones. Studies stable features of certain histone fractions, similar to those of were therefore carried out on a number of hepatomas with some other proteins, such as carbonic anhydrase (3).
    [Show full text]
  • Global Lysine Acetylome Analysis of LPS-Stimulated Hepg2 Cells Identified Hyperacetylation of PKM2 As a Metabolic Regulator in Sepsis
    International Journal of Molecular Sciences Article Global Lysine Acetylome Analysis of LPS-Stimulated HepG2 Cells Identified Hyperacetylation of PKM2 as a Metabolic Regulator in Sepsis Ann-Yae Na 1, Sanjita Paudel 1, Soyoung Choi 1, Jun Hyung Lee 2, Min-Sik Kim 2, Jong-Sup Bae 1 and Sangkyu Lee 1,* 1 BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea; [email protected] (A.-Y.N.); [email protected] (S.P.); [email protected] (S.C.); [email protected] (J.-S.B.) 2 Department of New Biology, Daegu Gyeongbuk Institute of Science & Technology, Daegu 42988, Korea; [email protected] (J.H.L.); [email protected] (M.-S.K.) * Correspondence: [email protected]; Tel.: +82-53-950-8571; Fax: +82-53-950-8557 Abstract: Sepsis-induced liver dysfunction (SILD) is a common event and is strongly associated with mortality. Establishing a causative link between protein post-translational modification and diseases is challenging. We studied the relationship among lysine acetylation (Kac), sirtuin (SIRTs), and the factors involved in SILD, which was induced in LPS-stimulated HepG2 cells. Protein hyperacetylation was observed according to SIRTs reduction after LPS treatment for 24 h. We identified 1449 Kac sites based on comparative acetylome analysis and quantified 1086 Kac sites on 410 proteins for Citation: Na, A.-Y.; Paudel, S.; Choi, S.; Lee, J.H.; Kim, M.-S.; Bae, J.-S.; Lee, acetylation. Interestingly, the upregulated Kac proteins are enriched in glycolysis/gluconeogenesis S. Global Lysine Acetylome Analysis pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) category.
    [Show full text]
  • Engineering an Acetyllysine Reader with Photocrosslinking Amino Acid for Interactome Profiling
    Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2021 Engineering an acetyllysine reader with photocrosslinking amino acid for interactome profiling Anirban Roy,a Soumen Barman,a Jyotirmayee Padhan and Babu Sudhamalla* Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal, India 741246 aEqual contribution Table of Contents 1. General materials, methods and equipment S2 2. Protein-peptide docking studies S2 3. Molecular modeling and molecular dynamics (MD) simulations S3 4. Mutagenesis, expression and purification of ATAD2B bromodomain S4 5. Fluorescence polarization (FP) assay S5 6. Isothermal titration calorimetry (ITC) S5 7. Circular dichroism spectroscopy S6 8. Thermal shift assay S6 9. Photo-crosslinking experiment with histone peptides and in-gel fluorescence S6 10. Mammalian cell culture S7 11. Acid extraction of histones S7 12. Photocrosslinking with hyperacetylated histone H4 and Western blotting S8 13. Preparation of HeLa cell lysate S8 14. Photocrosslinking with HeLa cell lysate and Western blotting S9 15. Supplementary figures and tables S10 16. References S24 S1 1. General materials, methods and equipment All the plasmids for bacterial expression are obtained as gifts from individual laboratories or purchased from addgene. Details of these constructs are given in sections below. Mutagenic primers are obtained from Sigma-Aldrich (Table S1). Commercially available competent bacterial cells were used for protein expression and mutagenesis. HeLa cells, obtained from the American Type Culture Collection (ATCC) and used in the current study following manufacturer’s protocol. All the antibodies used in the current study are purchased from established vendors and used following manufacturer’s protocol.
    [Show full text]
  • N-Acetylation of Arginine-Rich Hepatoma Histones1
    [CANCER RESEARCH 31, 468-470, April 1971] N-Acetylation of Arginine-rich Hepatoma Histones1 Paul Byvoetand Harold P. Morris Cellular and Molecular Biology, Division of Biological Sciences, University of Florida, Gainesville, Florida ¡P.B.¡,and Department of Biochemistry, Howard University College of Medicine. Washington, D. C. 20001 ¡H.P.M./ SUMMARY represents a fraction of the total number of sites available for acetylation (2). Previous work in this laboratory has shown that decay rates On the other hand, Starbuck et al. (11) have purified of histones and DNA isolated from deoxyribonucleoprotein of histone fractions which were either 100% acetylated at the normal and neoplastic rat tissues were approximately equal, NH2-terminal end or not at all. In addition, when isolated indicating that not only DNA but the nucleohistone complex nuclei were incubated in the presence of radioactive acetate, as a whole is metabolically inert. In contrast, the vV-acetyl incorporation of label appeared to occur primarily in groups in the combined arginine and slightly lysine-rich e-jV-acetyllysine of histones (6, 12). Thus far, all evidence histones from these same tissues were found to turn over at would therefore lead to the conclusion that the e-jV-acetyl much faster rates than whole histones or DNA, with exception groups on the internal lysine residues are metabolically active, of the Novikoff hepatoma, in which this turnover was wheras the a-jV-acetyl groups at the NH2-terminal ends are remarkably slow, approaching that of the histones. Studies stable features of certain histone fractions, similar to those of were therefore carried out on a number of hepatomas with some other proteins, such as carbonic anhydrase (3).
    [Show full text]
  • Synthesized Histones H3 and H4 (Chromatin/Nucleosome Assembly/Deblocking and Microsequencing) RICHARD E
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1237-1241, February 1995 Cell Biology Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4 (chromatin/nucleosome assembly/deblocking and microsequencing) RICHARD E. SOBEL*, RICHARD G. COOKt, CAROLYN A. PERRY*, ANTHONY T. ANNUNZIATOt, AND C. DAVID ALLIS*§ *Department of Biology, Syracuse University, Syracuse, NY 13244; tDepartment of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030; and *Department of Biology, Boston College, Chestnut Hill, MA 02167 Communicated by Salih J. Wakil, Baylor College of Medicine, Houston, 7X, October 12, 1994 ABSTRACT Newly synthesized histone H4 is deposited in deposited into macronuclei (4). By stain and by label, histone a diacetylated isoform in a wide variety of organisms. In extracted from these micronuclei is greatly enriched in di- Tetrahymena a specific pair of residues, lysines 4 and 11, have acetylated H4 and mono- and diacetylated forms of H3. been shown to undergo this modification in vivo. In this report, Because micronuclei are transcriptionally inactive, acetylation we demonstrate that the analogous residues, lysines 5 and 12, of newly synthesized H3 and H4 in micronuclei is clearly are acetylated in Drosophila and HeLa 114. These data strongly distinct from transcription-related acetylation in this system. suggest that deposition-related acetylation sites in H4 have Despite evidence suggesting a conserved pattern of depo- been highly, perhaps absolutely, conserved. In Tetrahymena sition-related H4 diacetylation, very few studies have at- and Drosophila newly synthesized histone H3 is also deposited tempted to ascertain the sites of diacetylation in newly syn- in several modified forms.
    [Show full text]
  • Measurement of Acetylation Turnover at Distinct Lysines in Human Histones Identifies Long-Lived Acetylation Sites
    ARTICLE Received 5 Feb 2013 | Accepted 26 Jun 2013 | Published 29 Jul 2013 DOI: 10.1038/ncomms3203 Measurement of acetylation turnover at distinct lysines in human histones identifies long-lived acetylation sites Yupeng Zheng1, Paul M. Thomas1 & Neil L. Kelleher1,2,3 Histone acetylation has long been determined as a highly dynamic modification associated with open chromatin and transcriptional activation. Here we develop a metabolic labelling scheme using stable isotopes to study the kinetics of acetylation turnover at 19 distinct lysines on histones H3, H4 and H2A. Using human HeLa S3 cells, the analysis reveals 12 sites of histone acetylation with fast turnover and 7 sites stable over a 30 h experiment. The sites showing fast turnover (anticipated from classical radioactive measurements of whole histones) have half-lives between B1–2 h. To support this finding, we use a broad-spectrum deacetylase inhibitor to verify that only fast turnover sites display 2–10-fold increases in acetylation whereas long-lived sites clearly do not. Most of these stable sites lack extensive functional studies or localization within global chromatin, and their role in non-genetic mechanisms of inheritance is as yet unknown. 1 Department of Molecular Biosciences, Northwestern University, Evanston, Illinois 60208, USA. 2 Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. 3 Department of Chemistry, Northwestern University, Evanston, Illinois 60208, USA. Correspondence and requests for materials should be addressed to N.L.K. (email: [email protected]). NATURE COMMUNICATIONS | 4:2203 | DOI: 10.1038/ncomms3203 | www.nature.com/naturecommunications 1 & 2013 Macmillan Publishers Limited.
    [Show full text]
  • Epigenetic Reader Domain
    Epigenetic Reader Domain Epigenetic regulators of gene expression and chromatin state include so-called writers, erasers, and readers of chromatin modifications.Well-characterized examples of reader domains include bromodomains typically binding acetyllysine and chromatin organization modifier (chromo), malignant brain tumor (MBT), plant homeodomain (PHD), and Tudor domains generally associating with methyllysine. Research on epigenetic readers has been tremendously influenced by the discovery of selective inhibitors targeting the bromodomain and extraterminal motif (BET) family of acetyl-lysine readers. The human genome encodes 46 proteins containing 61 bromodomains clustered into eight families. Distinct experimental approaches are used to identify the first BET inhibitors, GSK 525762A and (+)-JQ-1. The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing. This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. In many types of cancers including lymphomas and leukemia, EZH2 is postulated to exert its oncogenic effects via aberrant histone and DNA methylation, causing silencing of tumor suppressor genes. p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase. www.MedChemExpress.com 1 Epigenetic Reader Domain Inhibitors & Modulators (+)-JQ-1 (+)-JQ-1-aldehyde (JQ1) Cat. No.: HY-13030 Cat. No.: HY-131633A (+)-JQ-1 (JQ1) is a potent, specific, and (+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. reversible BET bromodomain inhibitor, with (+)-JQ-1-aldehyde can be uesd as a precursor to IC50s of 77 and 33 nM for the first and second synthesize PROTACs, which targets BET bromodomain (BRD4(1/2)).
    [Show full text]
  • Download.Php) 936
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.306696; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.306696; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A common binding motif in the ET domain of BRD3 forms polymorphic structural 2 interfaces with host and viral proteins 3 4 Sriram Aiyer1,2,#,¶, G.V.T. Swapna1,2,¶, Li-Chung Ma1,2 , Gaohua Liu2, ‡, Jingzhou Hao2,3, 5 Gordon Chalmers3, Brian C. Jacobs1, Gaetano T. Montelione2,3,*, Monica J. Roth1,2,* 6 7 1Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State 8 University of New Jersey, 675 Hoes Lane, Piscataway, NJ, 08854 USA, 2Department of 9 Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, The 10 State University of New Jersey, 675 Hoes Lane, Piscataway, NJ, 08854 USA. 3Department of 11 Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Sciences, 12 Rensselaer Polytechnic Institute, Troy, NY, 12180 USA 13 14 #Present address: Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La 15 Jolla, CA, 92037, USA. 16 ‡Present address: Nexomics Bioscience, Inc. 5 Crescent Ave, Rocky Hill, NJ 08553 17 COI Statement. GL is an officer of Nexomics Biosciences, Inc. GTM is a founder of Nexomics 18 Biosciences, Inc.
    [Show full text]
  • Quantitative Analysis of Histone Modifications: Formaldehyde Is a Source of Pathological N6- Formyllysine That Is Refractory to Histone Deacetylases
    Quantitative Analysis of Histone Modifications: Formaldehyde Is a Source of Pathological N6- Formyllysine That Is Refractory to Histone Deacetylases The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Edrissi, Bahar, Koli Taghizadeh, and Peter C. Dedon. “Quantitative Analysis of Histone Modifications: Formaldehyde Is a Source of Pathological N6-Formyllysine That Is Refractory to Histone Deacetylases.” Ed. James Swenberg. PLoS Genetics 9.2 (2013): e1003328. As Published http://dx.doi.org/10.1371/journal.pgen.1003328 Publisher Public Library of Science Version Final published version Citable link http://hdl.handle.net/1721.1/78350 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/2.5/ Quantitative Analysis of Histone Modifications: Formaldehyde Is a Source of Pathological N6- Formyllysine That Is Refractory to Histone Deacetylases Bahar Edrissi1, Koli Taghizadeh2, Peter C. Dedon1,2* 1 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 2 Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America Abstract Aberrant protein modifications play an important role in the pathophysiology of many human diseases, in terms of both dysfunction of physiological modifications and the formation of pathological modifications by reaction of proteins with endogenous electrophiles. Recent
    [Show full text]
  • A Chemical Biology Toolbox to Study Protein Methyltransferases and Epigenetic Signaling
    ARTICLE https://doi.org/10.1038/s41467-018-07905-4 OPEN A chemical biology toolbox to study protein methyltransferases and epigenetic signaling Sebastian Scheer 1, Suzanne Ackloo 2, Tiago S. Medina3, Matthieu Schapira 2,4, Fengling Li2, Jennifer A. Ward 5,6, Andrew M. Lewis 5,6, Jeffrey P. Northrop1, Paul L. Richardson 7, H. Ümit Kaniskan 8, Yudao Shen8, Jing Liu 8, David Smil 2, David McLeod 9, Carlos A. Zepeda-Velazquez9, Minkui Luo 10,11, Jian Jin 8, Dalia Barsyte-Lovejoy 2, Kilian V.M. Huber 5,6, Daniel D. De Carvalho3,12, Masoud Vedadi2,4, Colby Zaph 1, Peter J. Brown 2 & Cheryl H. Arrowsmith2,3,12 1234567890():,; Protein methyltransferases (PMTs) comprise a major class of epigenetic regulatory enzymes with therapeutic relevance. Here we present a collection of chemical probes and associated reagents and data to elucidate the function of human and murine PMTs in cellular studies. Our collection provides inhibitors and antagonists that together modulate most of the key regulatory methylation marks on histones H3 and H4, providing an important resource for modulating cellular epigenomes. We describe a comprehensive and comparative character- ization of the probe collection with respect to their potency, selectivity, and mode of inhi- bition. We demonstrate the utility of this collection in CD4+ T cell differentiation assays revealing the potential of individual probes to alter multiple T cell subpopulations which may have implications for T cell-mediated processes such as inflammation and immuno-oncology. In particular, we demonstrate a role for DOT1L in limiting Th1 cell differentiation and main- taining lineage integrity.
    [Show full text]
  • The Role of Dietary Histone Deacetylases (Hdacs) Inhibitors in Health and Disease
    Nutrients 2014, 6, 4273-4301; doi:10.3390/nu6104273 OPEN ACCESS nutrients ISSN 2072-6643 www.mdpi.com/journal/nutrients Review The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease Shalome A. Bassett 1,2,* and Matthew P. G. Barnett 1,2 1 Food Nutrition & Health Team, Food & Bio-based Products Group, AgResearch Limited, Grasslands Research Centre, Tennent Drive, Palmerston North 4442, New Zealand; E-Mail: [email protected] 2 Nutrigenomics New Zealand, Private Bag 92019, Auckland 1142, New Zealand * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +64-6-351-8056; Fax: +64-6-351-8032. Received: 31 July 2014; in revised form: 6 October 2014 / Accepted: 6 October 2014 / Published: 15 October 2014 Abstract: Modification of the histone proteins associated with DNA is an important process in the epigenetic regulation of DNA structure and function. There are several known modifications to histones, including methylation, acetylation, and phosphorylation, and a range of factors influence each of these. Histone deacetylases (HDACs) remove the acetyl group from lysine residues within a range of proteins, including transcription factors and histones. Whilst this means that their influence on cellular processes is more complex and far-reaching than histone modifications alone, their predominant function appears to relate to histones; through deacetylation of lysine residues they can influence expression of genes encoded by DNA linked to the histone molecule. HDAC inhibitors in turn regulate the activity of HDACs, and have been widely used as therapeutics in psychiatry and neurology, in which a number of adverse outcomes are associated with aberrant HDAC function.
    [Show full text]